Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$857.70 -0.6%	$857.99	$560.91 ▼ $953.58	$53.34B	0.45	355,474 shs	115,850 shs
GSK GSK	$52.74 +2.5%	$51.48	$35.45 ▼ $61.69	$106.69B	0.35	4.61 million shs	1.88 million shs
SNY Sanofi	$44.14 +1.0%	$43.30	$40.89 ▼ $52.68	$107.00B	0.34	3.61 million shs	1.83 million shs
TAK Takeda Pharmaceutical	$16.74 +1.7%	$16.11	$12.99 ▼ $18.90	$53.26B	-0.07	3.04 million shs	4.64 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+0.41%	-5.72%	-2.41%	+4.17%	+55.21%
GSK GSK	+0.33%	-2.12%	-1.50%	-9.96%	+36.05%
SNY Sanofi	+1.16%	+2.10%	-0.27%	-8.47%	-9.23%
TAK Takeda Pharmaceutical	+0.18%	-1.91%	+4.38%	-7.53%	+11.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$857.70 -0.6%	$857.99	$560.91 ▼ $953.58	$53.34B	0.45	355,474 shs	115,850 shs
GSK GSK	$52.74 +2.5%	$51.48	$35.45 ▼ $61.69	$106.69B	0.35	4.61 million shs	1.88 million shs
SNY Sanofi	$44.14 +1.0%	$43.30	$40.89 ▼ $52.68	$107.00B	0.34	3.61 million shs	1.83 million shs
TAK Takeda Pharmaceutical	$16.74 +1.7%	$16.11	$12.99 ▼ $18.90	$53.26B	-0.07	3.04 million shs	4.64 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+0.41%	-5.72%	-2.41%	+4.17%	+55.21%
GSK GSK	+0.33%	-2.12%	-1.50%	-9.96%	+36.05%
SNY Sanofi	+1.16%	+2.10%	-0.27%	-8.47%	-9.23%
TAK Takeda Pharmaceutical	+0.18%	-1.91%	+4.38%	-7.53%	+11.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.92	Moderate Buy	$1,037.61	20.76% Upside
GSK GSK	2.10	Hold	$53.00	0.49% Upside
SNY Sanofi	2.47	Hold	$49.50	12.47% Upside
TAK Takeda Pharmaceutical	2.25	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest TAK, GSK, SNY, and ARGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2026	GSK GSK	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
7/8/2026	SNY Sanofi	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$49.00
7/7/2026	ARGX argenex	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$890.00 ➝ $945.00
7/6/2026	ARGX argenex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
7/6/2026	GSK GSK	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Reduce ➝ Hold
7/2/2026	ARGX argenex	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,016.00 ➝ $1,088.00
6/29/2026	TAK Takeda Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/25/2026	ARGX argenex	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$940.00
6/24/2026	ARGX argenex	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,170.00 ➝ $1,180.00
6/23/2026	TAK Takeda Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
6/11/2026	GSK GSK	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)

(Data available from 7/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	12.58	$21.33 per share	40.29	$118.34 per share	7.26
GSK GSK	$43.07B	2.48	$6.18 per share	8.53	$10.32 per share	5.11
SNY Sanofi	$47.35B	2.25	$7.20 per share	6.11	$33.26 per share	1.32
TAK Takeda Pharmaceutical	$4.51T	0.01	$3.15 per share	5.28	$15.41 per share	1.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$22.46	38.12	25.47	1.06	31.31%	44.37%	37.55%	7/23/2026 (Estimated)
GSK GSK	$7.54B	$3.85	13.71	10.49	3.29	17.82%	44.28%	11.49%	7/28/2026 (Estimated)
SNY Sanofi	$8.84B	$3.58	12.28	8.53	1.10	16.95%	13.39%	7.58%	7/30/2026 (Estimated)
TAK Takeda Pharmaceutical	-$1.01B	$0.39	42.65	14.47	N/A	4.31%	11.20%	5.48%	7/30/2026 (Estimated)

Latest TAK, GSK, SNY, and ARGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2026	Q2 2026	SNY Sanofi	$1.09	N/A	N/A	N/A	$12.76 billion	N/A
7/30/2026	Q1 2027	TAK Takeda Pharmaceutical	$0.1716	N/A	N/A	N/A	$7.18 billion	N/A
7/28/2026	Q2 2026	GSK GSK	$1.27	N/A	N/A	N/A	$11.02 billion	N/A
7/23/2026	Q2 2026	ARGX argenex	$5.86	N/A	N/A	N/A	$1.45 billion	N/A
5/7/2026	Q1 2026	ARGX argenex	$5.74	$5.52	-$0.22	$5.52	$1.44 billion	$1.31 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
GSK GSK	$1.79	3.39%	-7.86%	46.49%	N/A
SNY Sanofi	$1.76	3.99%	+6.46%	49.16%	N/A
TAK Takeda Pharmaceutical	$0.48	2.87%	-6.89%	123.08%	N/A

Latest ARGX, GSK, SNY, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2026	GSK GSK	quarterly	$0.44	3.71%	5/15/2026	5/15/2026	7/9/2026
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.23	4.87
GSK GSK	0.80	0.79	0.52
SNY Sanofi	0.17	1.01	0.22
TAK Takeda Pharmaceutical	0.59	1.09	0.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
GSK GSK	15.74%
SNY Sanofi	14.03%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
GSK GSK	10.00%
SNY Sanofi	1.00%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.19 million	60.68 million	Optionable
GSK GSK	66,841	2.02 billion	1.82 billion	Optionable
SNY Sanofi	74,846	2.42 billion	2.40 billion	Optionable
TAK Takeda Pharmaceutical	47,000	3.18 billion	3.18 billion	Optionable

ARGX, GSK, SNY, and TAK Headlines

Recent News About These Companies

Takeda Pharmaceutical (NYSE:TAK) Sees Strong Trading Volume - Here's Why

2 hours ago | marketbeat.com

Bleakley Financial Group LLC Boosts Holdings in Takeda Pharmaceutical Co. $TAK

July 15 at 3:19 AM | marketbeat.com

Inside Takeda’s transformation: The pipeline strategy behind its next growth chapter

July 14 at 1:06 PM | labiotech.euL

Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products

July 12, 2026 | businesswire.com

Takeda Pharmaceutical (NYSE:TAK) Cut to "Hold" at Wall Street Zen

July 6, 2026 | americanbankingnews.com

Takeda’s New AI Drug Discovery Deal With Insilico Might Change The Case For Investing In Takeda Pharmaceutical (TSE:4502)

July 2, 2026 | finance.yahoo.com

Takeda, InSilico Strike AI Drug-Discovery Deal Worth Up to $600 Million

July 1, 2026 | wsj.com

Is Takeda Pharmaceutical Company Limited (TAK) Stock Positioned for Growth After Strong LATITUDE Atlas Study Data?

June 30, 2026 | insidermonkey.com

Hitachi, Carlyle, Permira among bidders for $1 bln Takeda unit-sources

June 29, 2026 | finance.yahoo.com

Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda

June 26, 2026 | finance.yahoo.com

Takeda's 1st female CEO leans into AI to shape biopharma business

June 26, 2026 | asia.nikkei.com

Takeda Pharmaceutical Company Limited (TAK) Shareholder/Analyst Call - Slideshow

June 24, 2026 | seekingalpha.com

Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO

June 24, 2026 | businesswire.com

Pharmaceutical Company Takeda Cuts 200 Jobs in Austria - Mainly in Vienna

June 23, 2026 | vienna.atV

Takeda's Zasocitinib Achieved Significantly Greater Complete Skin Clearance Than Deucravacitinib in Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

June 23, 2026 | newswire.ca

Takeda (TSE:4502) Unveils Phase 3 Wins In Narcolepsy And Psoriasis

June 16, 2026 | finance.yahoo.com

New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1

June 15, 2026 | lasvegassun.comL

New Pivotal Study Data Show Takeda's Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1

June 15, 2026 | businesswire.com

Takeda’s oral TYK2 blocker outperforms Sotyktu in PsA trial

June 12, 2026 | yahoo.com

Largest Mass. biotech employer is axing thousands of jobs. Cambridge employees are next

June 12, 2026 | masslive.comM

Takeda Pharmaceutical: The Downside Was Forecastable

June 11, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARGX, GSK, SNY, and TAK Company Descriptions

argenex NASDAQ:ARGX

$857.70 -5.23 (-0.61%)

As of 02:25 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

GSK NYSE:GSK

$52.74 +1.29 (+2.50%)

As of 02:26 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Sanofi NASDAQ:SNY

$44.14 +0.46 (+1.04%)

As of 02:26 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Takeda Pharmaceutical NYSE:TAK

$16.74 +0.29 (+1.73%)

As of 02:26 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TAK, GSK, SNY, and ARGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TAK, GSK, SNY, and ARGX Earnings

Compare Dividends

Latest ARGX, GSK, SNY, and TAK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARGX, GSK, SNY, and TAK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARGX, GSK, SNY, and TAK Company Descriptions

argenex NASDAQ:ARGX

GSK NYSE:GSK

Sanofi NASDAQ:SNY

Takeda Pharmaceutical NYSE:TAK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TAK, GSK, SNY, and ARGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TAK, GSK, SNY, and ARGX Earnings

Compare Dividends

Latest ARGX, GSK, SNY, and TAK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARGX, GSK, SNY, and TAK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARGX, GSK, SNY, and TAK Company Descriptions

argenex NASDAQ:ARGX

GSK NYSE:GSK

Sanofi NASDAQ:SNY

Takeda Pharmaceutical NYSE:TAK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools